{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:35:03Z","timestamp":1783049703769,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00280-024-04642-y","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T11:02:32Z","timestamp":1709377352000},"page":"635-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory\/relapsed therapy-related acute myeloid leukemia"],"prefix":"10.1007","volume":"94","author":[{"given":"Wenqiang","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhewei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjia","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"4642_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev.genom.3.032802.115046","volume":"3","author":"LM Kelly","year":"2002","unstructured":"Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179\u2013198","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"4642_CR2","first-page":"1","volume":"6","author":"AM Almeida","year":"2016","unstructured":"Almeida AM, Ramos F (2016) Acute myeloid leukemia in the older adults. Leuk Res Rep 6:1\u20137","journal-title":"Leuk Res Rep"},{"key":"4642_CR3","doi-asserted-by":"publisher","first-page":"204062071986064","DOI":"10.1177\/2040620719860645","volume":"10","author":"ES Winer","year":"2019","unstructured":"Winer ES, Stone RM (2019) Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol 10:2040620719860645","journal-title":"Ther Adv Hematol"},{"issue":"14","key":"4642_CR4","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1200\/JCO.20.02342","volume":"39","author":"T Cluzeau","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R et al (2021) Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM). J Clin Oncol 39(14):1575\u20131583","journal-title":"J Clin Oncol"},{"issue":"31","key":"4642_CR5","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H et al (2015) Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33(31):3641\u20133649","journal-title":"J Clin Oncol"},{"issue":"10","key":"4642_CR6","first-page":"937","volume":"84","author":"G Leone","year":"1999","unstructured":"Leone G, Mele L, Pulsoni A, Equitani F, Pagano L (1999) The incidence of secondary leukemias. Haematologica 84(10):937\u2013945","journal-title":"Haematologica"},{"issue":"15","key":"4642_CR7","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"M Miesner","year":"2010","unstructured":"Miesner M, Haferlach C, Bacher U et al (2010) Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS\/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as \u201cAML not otherwise specified\u201d (AML-NOS) or \u201cAML with myelodysplasia-related changes\u201d (AML-MRC). Blood 116(15):2742\u20132751","journal-title":"Blood"},{"issue":"3","key":"4642_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354\u2013365","journal-title":"Blood"},{"issue":"20","key":"4642_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"5","key":"4642_CR10","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.23966","volume":"90","author":"L Fianchi","year":"2015","unstructured":"Fianchi L, Pagano L, Piciocchi A et al (2015) Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol 90(5):E80\u2013E85","journal-title":"Am J Hematol"},{"issue":"5","key":"4642_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","volume":"10","author":"B Samra","year":"2020","unstructured":"Samra B, Richard-Carpentier G, Kadia TM et al (2020) Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47","journal-title":"Blood Cancer J"},{"issue":"5","key":"4642_CR12","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1080\/10428194.2021.2012666","volume":"63","author":"SF Huntington","year":"2022","unstructured":"Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM (2022) Treatment patterns, economic burden, and overall survival in US Medicare advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015\u20132020. Leuk Lymphoma 63(5):1180\u20131190","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"4642_CR13","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.3390\/ijms21072528","volume":"21","author":"IZ Uras","year":"2020","unstructured":"Uras IZ, Sexl V, Kollmann K (2020) CDK6 inhibition: a novel approach in AML management. Int J Mol Sci 21(7):2528","journal-title":"Int J Mol Sci"},{"key":"4642_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153\u2013166","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"4642_CR15","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR et al (2012) Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119(20):4597\u20134607","journal-title":"Blood"},{"issue":"10","key":"4642_CR16","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","volume":"23","author":"B Geoerger","year":"2017","unstructured":"Geoerger B, Bourdeaut F, DuBois SG et al (2017) A phase I study of the CDK4\/6 inhibitor Ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res 23(10):2433\u20132441","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4642_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM et al (2016) Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6(7):740\u2013753","journal-title":"Cancer Discov"},{"issue":"7","key":"4642_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","volume":"2","author":"MA Dickson","year":"2016","unstructured":"Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2(7):937\u2013940","journal-title":"JAMA Oncol"},{"key":"4642_CR19","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/blood.V128.22.1608.1608","volume":"128","author":"S Fr\u00f6hling","year":"2016","unstructured":"Fr\u00f6hling S, Agrawal M, Jahn N et al (2016) CDK4\/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23\u201314 trial. Blood 128:1608","journal-title":"Blood"},{"issue":"Suppl S1","key":"4642_CR20","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1182\/blood-2018-99-117334","volume":"132","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, Konopleva MY, Garcia-Manero G et al (2018) Phase I study of Palbociclib alone and in combination in patients with relapsed and refractory (R\/R) leukemias. Blood 132(Suppl S1):4057","journal-title":"Blood"},{"key":"4642_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113527","volume":"153","author":"A Wang","year":"2022","unstructured":"Wang A, Fang M, Jiang H et al (2022) Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. Biomed Pharmacother 153:113527","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"4642_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2019003267","volume":"136","author":"J Schmoellerl","year":"2020","unstructured":"Schmoellerl J, Barbosa IAM, Eder T et al (2020) CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood 136(4):387\u2013400","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04642-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T15:02:13Z","timestamp":1727535733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04642-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["4642"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04642-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"13 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Consent obtained from patient for this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}